$CRBU

Caribou Biosciences, Inc. (CRBU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update -- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-ce

Caribou Biosciences, Inc. (CRBU) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. crbu-20260617 FALSE 0001619856 0001619856 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________ FORM 8-K ________________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the

Caribou Biosciences announced its participation in the 4th Annual BioConnect Investor Conference hosted by H.C. Wainwright in New York City, where it will showcase its CRISPR-based cell therapies to investors and industry leaders. This appearance is part of the company's ongoing active conference schedule, which recently included CEO Rachel Haurwitz speaking at the BofA Securities Health Care Conference and a Bank of America webcast. The company continues to actively engage with investors and stakeholders to highlight its advancements in biotechnology.

Caribou Biosciences (CRBU) reported stronger-than-expected Q1 2026 earnings, with EPS of -$0.26 beating estimates by $0.07 and revenue of $2.4 million exceeding forecasts. Following this news and the announcement of their participation in a H.C. Wainwright conference, the company's stock surged 4.43% to $2.12 on May 13. Caribou Biosciences develops allogeneic CAR-T cell therapies using its proprietary CRISPR-based chRDNA platform for cancer and autoimmune diseases, with lead candidates like CB-010 and CB-011 (which received FDA RMAT designation) driving pipeline progress.

This article identifies promising "penny stocks" for May 2026, focusing on companies with strong financials and growth potential in a flat market. It highlights three specific companies: Whitehawk Therapeutics (WHWK), Caribou Biosciences (CRBU), and Zion Oil & Gas (ZNOG), detailing their current financial status, operations, and recent developments. The article emphasizes that while these companies are pre-revenue or currently unprofitable, they show potential due to factors like significant investor interest, advancing clinical trials, or strong balance sheets despite other challenges.

Caribou Biosciences, Inc. announced that its management will participate in two upcoming investor conferences: the Citi 2026 Virtual Oncology Leadership Summit on February 19, 2026, and the Leerink Global Healthcare Conference on March 10, 2026. The company, a clinical-stage CRISPR genome-editing biopharmaceutical firm, will present at both events, with webcasts available for playback.

Clear Street analyst William Maughan has initiated coverage on Caribou Biosciences (CRBU.US) with a "buy" rating and set a target price of $13. Maughan has a 47.3% success rate and an average return of 22.5% over the past year, according to TipRanks data. This information is provided for informational purposes and is not an investment recommendation.

Caribou Biosciences (CRBU) delivered earnings and revenue surprises of +16.67% and -14.34%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

BERKELEY, Calif., Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Caribou Biosciences, Inc. ( NASDAQ:CRBU ) , a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the following investor conferences:

BERKELEY, Calif., Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Caribou Biosciences, Inc. ( Nasdaq: CRBU ) , a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the following investor conferences: ...